Here are the 10-Q quarterly reports from Cardiff Lexingto (CDIXD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDIXD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIXD filings page.
Cardiff Lexington Corporation reported a larger loss for the three months ended March 31, 2026 while relying heavily on debt financing. Revenue was $2,222,280, down from $2,915,567 a year earlier, reducing gross profit to $1,318,055. Operating results swung to a loss of $511,159, primarily due to $664,196 of share-based compensation and ongoing selling, general and administrative costs.
The bottom line was driven by $1,910,737 of interest expense and a $668,821 loss on derivative liabilities, producing a net loss of $3,092,074 and a basic and diluted loss per share of $0.23. Operating cash use was modest at $16,730, but the company raised $381,702 from financing, including $845,000 of new convertible notes.
At March 31, 2026, Cardiff held $683,507 in cash and $22,890,899 of accounts receivable tied to lien-based medical services, funded in part by an $18,922,173 line of credit under a $23,000,000 facility and $1,095,000 of convertible notes. Total liabilities were $24,630,858 against stockholders’ equity of $3,876,456 and an accumulated deficit of $82,855,513. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional capital.